Anaveon 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
7 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ANV419 / Anaveon
PragmaTIL, NCT06630611: Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer

Recruiting
2
40
Europe
NMA-LD regimen, Cyclophosphamide and Fludarabine, Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion, High dose IL-2, IL-2 analog
Vall d'Hebron Institute of Oncology, Banc de Sang i Teixits
Melanoma, Non Small Cell Lung Cancer, Cervical Cancer
09/29
09/29
2020-004569-37: A study of ANV419 alone or in combination , in patients with relapsed/refractory advanced solid tumors. Un estudio de ANV419 solo o en combinación en pacientes con tumores sólidos avanzados recidivantes/refractarios

Not yet recruiting
1/2
75
Europe
ANV419, ANV419, Concentrate for solution for infusion
Anaveon AG, Anaveon AG
Relapsed/refractory advanced solid tumors Tumores Sólidos Avanzados Recidivantes/Refractarios., Relapsed/refractory advanced solid tumors Tumores Sólidos Avanzados Recidivantes/Refractarios., Diseases [C] - Cancer [C04]
 
 
2021-006711-29: A study of ANV419 alone or in combination with approved treatment in patients with cutaneous melanoma

Not yet recruiting
1/2
130
Europe
ANV419, ANV419, Solution for infusion, KEYTRUDA, YERVOY
Anaveon AG, Anaveon AG
Unresectable or Metastatic Cutaneous Melanoma with prior Anti PD 1/Anti-PD-L1 Antibody Treatment, Cutaneous Melanoma that had already been treated and is now unresectable or metastatic, Diseases [C] - Cancer [C04]
 
 
OMNIA-1, NCT05578872 / 2021-006711-29: A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma ().

Completed
1/2
29
Europe, US
ANV419
Anaveon AG, Anaveon AG
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
08/24
08/24
OMNIA-2, NCT05641324: A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma

Terminated
1
4
Europe
ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab
Anaveon AG
Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease, Hematologic Diseases
07/23
07/23
ANV419-001, NCT04855929 / 2020-004569-37: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.

Completed
1
55
Europe
ANV419, Ipilimumab
Anaveon AG, Anaveon AG
Advanced Solid Tumor, Adult Disease, Lung Cancer
07/24
07/24
BaseTIL-03M, NCT05869539: ACT-TIL and ANV419 for Advanced Melanoma.

Recruiting
1
10
Europe
Combination of Tumor-infiltrating lymphocyte transfer with ANV419
University Hospital, Basel, Switzerland, Anaveon AG
Advanced Melanoma
06/25
06/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ANV419 / Anaveon
PragmaTIL, NCT06630611: Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer

Recruiting
2
40
Europe
NMA-LD regimen, Cyclophosphamide and Fludarabine, Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion, High dose IL-2, IL-2 analog
Vall d'Hebron Institute of Oncology, Banc de Sang i Teixits
Melanoma, Non Small Cell Lung Cancer, Cervical Cancer
09/29
09/29
2020-004569-37: A study of ANV419 alone or in combination , in patients with relapsed/refractory advanced solid tumors. Un estudio de ANV419 solo o en combinación en pacientes con tumores sólidos avanzados recidivantes/refractarios

Not yet recruiting
1/2
75
Europe
ANV419, ANV419, Concentrate for solution for infusion
Anaveon AG, Anaveon AG
Relapsed/refractory advanced solid tumors Tumores Sólidos Avanzados Recidivantes/Refractarios., Relapsed/refractory advanced solid tumors Tumores Sólidos Avanzados Recidivantes/Refractarios., Diseases [C] - Cancer [C04]
 
 
2021-006711-29: A study of ANV419 alone or in combination with approved treatment in patients with cutaneous melanoma

Not yet recruiting
1/2
130
Europe
ANV419, ANV419, Solution for infusion, KEYTRUDA, YERVOY
Anaveon AG, Anaveon AG
Unresectable or Metastatic Cutaneous Melanoma with prior Anti PD 1/Anti-PD-L1 Antibody Treatment, Cutaneous Melanoma that had already been treated and is now unresectable or metastatic, Diseases [C] - Cancer [C04]
 
 
OMNIA-1, NCT05578872 / 2021-006711-29: A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma ().

Completed
1/2
29
Europe, US
ANV419
Anaveon AG, Anaveon AG
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
08/24
08/24
OMNIA-2, NCT05641324: A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma

Terminated
1
4
Europe
ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab
Anaveon AG
Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease, Hematologic Diseases
07/23
07/23
ANV419-001, NCT04855929 / 2020-004569-37: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.

Completed
1
55
Europe
ANV419, Ipilimumab
Anaveon AG, Anaveon AG
Advanced Solid Tumor, Adult Disease, Lung Cancer
07/24
07/24
BaseTIL-03M, NCT05869539: ACT-TIL and ANV419 for Advanced Melanoma.

Recruiting
1
10
Europe
Combination of Tumor-infiltrating lymphocyte transfer with ANV419
University Hospital, Basel, Switzerland, Anaveon AG
Advanced Melanoma
06/25
06/25

Download Options